Alkermes to Showcase Sleep Medicine Data at Sleep Europe 2026
Event summary
- Alkermes will present two oral presentations and six posters at Sleep Europe 2026, showcasing data on Alixorexton and LUMRYZ.
- New data from the Vibrance-1 phase 2 study of Alixorexton in adults with narcolepsy type 1 will be presented.
- Results from the phase 3 REVITALYZ study evaluating LUMRYZ in adults with idiopathic hypersomnia will be shared.
- Alkermes acquired Avadel Pharmaceuticals plc, adding LUMRYZ to its sleep portfolio.
- Alkermes aims to advance differentiated treatment approaches for narcolepsy and idiopathic hypersomnia.
The big picture
Alkermes is positioning itself as a leader in sleep medicine research, leveraging its recent acquisition of Avadel Pharmaceuticals to expand its portfolio. The company's focus on narcolepsy and idiopathic hypersomnia aligns with growing interest in treating rare neurological disorders. The strategic anomaly here is the breadth of data being presented, underscoring Alkermes' commitment to advancing differentiated treatment approaches in the sleep medicine space.
What we're watching
- Regulatory Pathway
- Whether the FDA and European Commission will grant further approvals for Alixorexton and LUMRYZ in new indications.
- Clinical Success
- The pace at which Alkermes can translate positive phase 2 and 3 data into commercial success for Alixorexton and LUMRYZ.
- Market Competition
- How Alkermes will differentiate its sleep medicine portfolio in a competitive market.
